查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
基因轉移系統市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)
市場調查報告書
商品編碼
1273341

基因轉移系統市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Gene Delivery Systems Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預測期內，基因轉移系統市場的複合年增長率預計為 7.3%。

COVID-19 對基因遞送系統市場產生了重大影響。 例如，Drug Discovery Today 於 2021 年 10 月發表的一篇文章指出，由於 COVID-19 大流行，研究、生產、臨床開發和所有市場推介都嚴重中斷。 在針對罕見、危及生命的疾病的 CGT 中，遠程醫療已被證明是減少臨床試驗中後續損失的有力工具。 此外，Prime Therapeutics在美國COVID-19流行初期推出了基因治療再保險產品PreserveRx，支持當時唯一可用的基因治療藥物Luxturna和Zolgensma。 Prime 已與製造商 Novartis Gene Therapy 達成協議，以在 2021 年取得基於價值的結果。 此外，2021 年 8 月，在美國監管機構解除限制後，Novartis將啟動一項新的 3 期試驗，以擴大 Zolgensma 的使用範圍，單次治療每名患者的費用為 210 萬美元。 在市場參與者在大流行期間採取這些行動之後，預計市場將在預測期內復蘇並呈現強勁增長。

推動市場增長的主要因素是慢性病發病率和患病率的上升以及藥物輸送技術的不斷進步。 美國等發達國家典型的慢性病包括心血管病、傳染病、癌症和糖尿病等。 例如，根據美國癌症協會的 2023 年更新，2023 年美國可能診斷出 200 萬新癌症病例。 此外，國家醫學圖書館 2021 年 6 月發表的一篇論文指出，西班牙報告稱，2021 年 2 型糖尿病患者的心血管疾病患病率在 6.9% 至 40.8% 之間。我來了。 數據顯示，冠心病患病率從4.7%到37%，中風從3.5%到19.6%，外周動脈疾病從2.5%到13.0%，心力衰竭從4.3%到20.1%。 由於慢性病發病率高，對增強型診斷方法的需求不斷增加，這被認為是推動市場發展的動力。

此外，預計在預測期內，全球基因組學領域不斷增加的研究和開發也將有助於市場增長。 例如，2022 年 5 月，我們贊助了一項臨床研究，評估接受 Pell Bio-Med Technology 製造的基於慢病毒的基因編輯免疫細胞的患者的安全性和有效性。 預計基因轉移系統領域的此類研究舉措將在預測期內推動市場增長。

產品發布、擴張和合作夥伴關係等主要市場參與者的各種舉措預計將在預測期內推動市場增長。 例如，2021 年 6 月，VIVEbiotech 在西班牙開設了一家新的慢病毒載體製造工廠，擴大了其生產用於細胞和基因治療的慢病毒載體的能力。 預計此類新興市場的發展將在預測期內推動市場增長。

但是，高昂的治療成本預計會在預測期內抑制所研究市場的增長。

基因轉移系統市場趨勢

病毒基因轉移系統板塊有望成為基因轉移系統市場最大份額

病毒基因轉移系統由不能複制的修飾病毒組成，它可以將基因傳遞到細胞中以提供表達。 腺病毒、逆轉錄病毒和慢病毒已被用作病毒基因轉移系統。 病毒基因遞送系統由於其長期和短期表達、治療基因的功效以及過去幾年技術進步不斷增加等屬性，在醫療保健行業呈現出許多增長機會，因此在預測期內預計將佔據很大的市場份額。 此外，癌症和心血管疾病等慢性病患病率的增加也有助於市場增長。 例如，根據英國心臟基金會 England Factsheet 於 2022 年 1 月發布的數據，英國約有 640 萬人患有心血管疾病。 根據疾病預防控制中心的數據，到 2021 年，美國約有 1820 萬 20 歲及以上的成年人患有冠狀動脈疾病 (CAD)。 在美國，心髒病是導致死亡的主要原因。 因此，慢性病的增加將顯著推動被調查市場的增長。

由於各國政府更加關注治理並提高對這些療法的認識，這些基因轉移系統正在迅速獲得全世界的認可。 例如，根據世界經濟論壇 2022 年 9 月的報告，個性化基因治療的獨特性使其難以在傳統框架內進行監管。 同一消息人士稱，到 2030 年，預計美國將批准 60 多種基因療法，FDA 將不得不迅速發展，以正確確定這些新療法的安全性和有效性。 這些監管變化已波及全球，各國協調監管要求，使公司更容易將基因治療藥物更快地推向更多市場。 預計這種全球努力將促進基因治療的引入和基因轉移系統的利用，從而導致市場增長。

基因傳遞系統市場-IMG1

預計在預測期內北美市場將出現顯著增長

在預測期內，預計北美將保持其在整個基因轉移系統市場的主導地位。 慢性病患病率上升、技術進步以及大公司的強大影響力等因素正在推動該地區的市場增長。 例如，美國癌症協會2023年1月公佈的數據估計，2023年美國將有1958310例癌症新確診病例。 2019 年，美國 65 歲及以上人口有 5410 萬人（佔總人口的 16%），預計到 2040 年將增長到 21.6%。

此外，主要市場參與者的存在以及他們實施的關鍵戰略（例如夥伴關係和協作）也有助於市場增長。 例如，根據 2021 年 6 月的新聞報導，加拿大衛生部已經批准了五種基因治療藥物（Kymriah、Yescarta、Spinraza、Luxturna 和 Abecma），還有更多藥物正在研發中。 根據正在進行的臨床試驗的數量，未來幾年每年可批准 10 至 20 種基因治療藥物。 此外，政府資助基因治療領域的研究是該市場的主要增長動力之一。 例如，根據 2022 年 5 月發布的新聞報導，Virica Biotech 正在與加拿大政府合作，幫助製造 aav-lpl（脂蛋白脂肪□）基因療法來治療脂蛋白脂肪□缺乏症。 Bilika 從加拿大創新、科學和經濟發展部 (ISED) 獲得的 40,000 美元資金用於支持加拿大國家研究委員會 (NRC) 的細胞和基因治療挑戰計劃的活動。

基因傳遞系統市場-IMG2

基因轉移系統行業概況

基因轉移系統市場具有整合性，多家公司在全球和區域開展業務。 競爭格局包括幾個區域以及具有市場份額的知名國際參與者，例如Pfizer, Inc.、Becton, Dickinson and Company、Takara Bio、Novartis AG、F. Hoffmann-La Roche Ltd。我在這裡。

其他福利：

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 調查假設和市場定義
  • 本次調查的範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 慢性病和生活方式相關疾病的負擔增加
    • 生物製藥公司的研究技術進步
  • 市場製約因素
    • 飆升的治療費用
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 通過交付系統
    • 病毒基因轉移系統
      • 腺病毒系統
      • 慢病毒系統
      • 逆轉錄病毒系統
      • 其他病毒基因轉移系統
    • 非病毒基因轉移
    • 複合混合交付系統
  • 通過使用
    • 腫瘤科
    • 感染
    • 心血管疾病
    • 糖尿病
    • 呼吸系統疾病
    • 其他用途
  • 按給藥途徑
    • 口語
    • 注射
    • 鼻內
    • 其他給藥途徑
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Pfizer Inc.
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Becton, Dickinson and Company
    • Takara Bio
    • Shenzhen SiBiono GeneTech Co. Ltd
    • Bayer AG
    • Amgen Inc.
    • Shanghai Sunway Biotech Co. Ltd
    • Genezen
    • GenScript ProBio
    • Batavia Biosciences
    • Sirion-Biotech GmbH

第七章市場機會與未來趨勢

簡介目錄
Product Code: 68634

The gene delivery systems market is anticipated to register a CAGR of 7.3% over the forecast period.

COVID-19 had a significant impact on the gene delivery systems market. For instance, as per an article published by Drug Discovery Today in October 2021, the research, production, clinical development, and market introduction of cell and gene therapy (CGTs) for diseases unrelated to COVID-19 have all been significantly disrupted because of the COVID-19 pandemic. For CGTs with indications for rare, life-threatening conditions, telemedicine is found to be a potent tool to reduce the loss of follow-ups in clinical trials. Furthermore, Prime Therapeutics launched its PreserveRx gene therapy reinsurance product in the initial phase of COVID-19's spread across the United States to support the only two gene therapies available at the time, Luxturna and Zolgensma. Prime coordinated contracting with the manufacturer Novartis Gene Therapy for value-based outcomes in 2021. Further, in August 2021, Novartis launched a new phase three study to expand the use of Zolgensma, the one-time therapy at USD 2.1 million per patient treatment after the U.S. regulator lifted restrictions. Following these initiatives taken by the market players during the pandemic, the market has recovered and is expected to show robust growth over the forecast period.

The significant factors contributing to the market growth are the rising incidence and prevalence of chronic diseases and the increasing technological advancement in drug delivery. Some leading chronic diseases in developed countries, such as the United States, are cardiovascular diseases, infectious diseases, cancer, diabetes, and others. For instance, as per a 2023 update from the American Cancer Society, 2 million new cancer cases are likely to be diagnosed in the United States in 2023. Additionally, an article published by the National Library of Medicine, in June 2021 mentioned that in Spain, the reported prevalence of cardiovascular diseases among patients with type 2 diabetes ranged from 6.9% to 40.8% in 2021. According to the same source, the prevalence of coronary heart disease ranged from 4.7% to 37%, stroke from 3.5% to 19.6%, peripheral artery disease from 2.5% to 13.0%, and heart failure from 4.3% to 20.1%. The high incidence of chronic diseases is likely to increase the demand for substantial diagnostic procedures, which drives the market.

Moreover, the increasing ongoing research and development in the field of genomics worldwide are also expected to contribute to the market growth over the forecast period. For instance, in May 2022, Pell Bio-Med Technology Co., Ltd., sponsored a clinical study to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune cells manufactured by Pell Bio-Med Technology Co. Ltd. Such research initiatives in the field of gene delivery systems are anticipated to boost the market growth over the forecast period.

Various initiatives taken by the key market players such as product launches, expansion, and partnerships are expected to boost the market's growth during the forecast period. For instance, in June 2021, VIVEbiotech opened its new lentiviral vector manufacturing facilities in Spain, expanding the capacity for lentiviral vectors for use in cell and gene therapies. Such developments are expected to drive the market's growth over the forecast period.

However, the high cost of the treatment is expected to restrain the growth of the studied market over the forecast period.

Gene Delivery Systems Market Trends

Viral Gene Delivery Systems Segment is Expected to Hold the Largest Share in the Gene Delivery Systems Market

Viral gene delivery systems consist of viruses that are modified to be replication-deficient, which can deliver the genes to the cells to provide expression. Adenoviruses, retroviruses, and lentiviruses are used for viral gene delivery. Viral gene delivery systems are likely to hold a significant market share over the forecast period owing to attributes such as long-term expression and short-term expression, the efficacy of therapeutic genes, and the rising advancement in technology over the last few years which have opened up many opportunities for growth in the healthcare industry. The increase in the prevalence of chronic diseases, such as cancer and cardiovascular disorders, has also aided in market growth. For instance, according to the British Heart Foundation England Factsheet, published in January 2022, about 6.4 million people are living with cardiovascular diseases in England. Also, according to the CDC, in 2021, around 18.2 million adults aged 20 and older had coronary artery disease (CAD) in the United States. Heart disease is the leading cause of death among people in the United States. Thus, the rise in chronic diseases will significantly drive the growth of the studied market.

The growing emphasis on governing and raising awareness about these treatments by governments in different countries has resulted in the rapid acceptance of these gene delivery systems worldwide. For instance, as per the September 2022 report from World Economic Forum, the unique nature of personalized gene therapy treatments makes them difficult to regulate within traditional frameworks. The same source stated that, in the United States, over 60 gene therapies are expected to receive approval by 2030, forcing the FDA to quickly evolve to adequately judge the safety and efficacy of these novel treatments. These regulatory changes are creating ripple effects around the globe as countries seek to converge their regulatory requirements, making it easier and quicker for companies to bring their gene therapies to more markets sooner. Such initiatives around the globe are likely to adopt gene therapy and thereby utilize the gene delivery systems and leading to market growth.

Gene Delivery Systems Market - IMG1

North America is Likely to Show a Significant Market Growth Over the Forecast Period

North America is expected to maintain its overall gene delivery systems market supremacy throughout the forecast period. The factors such as the rising prevalence of chronic diseases, technological advancement, and the domicile presence of major players have been driving the market growth in the region. For instance, per the data published by the American Cancer Society in January 2023, an estimated 1,958,310 new cancer cases will be diagnosed in the United States in 2023. In addition, in the US, the population aged 65 or more was 54.1 million (16% of the total population) in 2019, which is estimated to be 21.6% by 2040.

Additionally, the presence of major market players and key strategies implemented by them, such as partnerships and collaborations, are also contributing to the market growth. For instance, as per the June 2021 news report, Health Canada approved five gene therapies (Kymriah, Yescarta, Spinraza, Luxturna, and Abecma), and there are more in the pipeline. Based on the number of clinical trials in progress, there are likely to be 10-20 gene therapy products approved every year for the next few years. Moreover, government funding in the field of gene therapy to conduct research is one of the primary growth factors of the studied market. For instance, as per a news report published in May 2022, Virica Biotech collaborated with the government of Canada to support the manufacturing of an aav-lpl (lipoprotein lipase) gene therapy to treat lipoprotein lipase deficiency. The USD 40,000 in funding from Innovation, Science and Economic Development Canada (ISED) received by Virica was used to support its work with the National Research Council (NRC) of Canada's Cell and Gene Therapy Challenge program.

Gene Delivery Systems Market - IMG2

Gene Delivery Systems Industry Overview

The gene delivery systems market is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well-known, including Pfizer, Inc., Becton, Dickinson and Company, Takara Bio, Novartis AG, and F. Hoffmann-La Roche Ltd, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Chronic Diseases and Lifestyle Disorders
    • 4.2.2 Technological Advancements in Research by Biopharmaceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Delivery Systems
    • 5.1.1 Viral Gene Delivery Systems
      • 5.1.1.1 Adenovirus Systems
      • 5.1.1.2 Lentiviral Systems
      • 5.1.1.3 Retroviral Systems
      • 5.1.1.4 Other Viral Gene Delivery Systems
    • 5.1.2 Non-viral Gene Delivery
    • 5.1.3 Combined Hybrid Delivery Systems
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Infectious Diseases
    • 5.2.3 Cardiovascular Disorders
    • 5.2.4 Diabetes
    • 5.2.5 Pulmonary Disorders
    • 5.2.6 Other Applications
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Injectable
    • 5.3.3 Nasal
    • 5.3.4 Other Routes of Administration
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer Inc.
    • 6.1.2 Novartis AG
    • 6.1.3 F. Hoffmann-La Roche AG
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Takara Bio
    • 6.1.6 Shenzhen SiBiono GeneTech Co. Ltd
    • 6.1.7 Bayer AG
    • 6.1.8 Amgen Inc.
    • 6.1.9 Shanghai Sunway Biotech Co. Ltd
    • 6.1.10 Genezen
    • 6.1.11 GenScript ProBio
    • 6.1.12 Batavia Biosciences
    • 6.1.13 Sirion-Biotech GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS